1. Signaling Pathways
  2. Epigenetics
    TGF-beta/Smad
  3. PKC

PKC

Protein kinase C

PKC (Protein kinase C) is a family of protein kinase enzymes that are involved in controlling the function of otherproteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins. PKC enzymes in turn are activated by signals such as increases in the concentration of diacylglycerol (DAG) or calcium ions (Ca2+). Hence PKC enzymes play important roles in several signal transduction cascades. The PKC family consists of 15 isozymes in humans: PKC-α (PRKCA), PKC-β1 (PRKCB), PKC-β2 (PRKCB), PKC-γ (PRKCG), PKC-δ (PRKCD), PKC-δ1 (PRKD1), PKC-δ2 (PRKD2), PKC-δ3 (PRKD3), PKC-ε (PRKCE), PKC-η (PRKCH), PKC-θ (PRKCQ), PKC-ι (PRKCI), PKC-ζ (PRKCZ), PK-N1 (PKN1), PK-N2 (PKN2), PK-N3 (PKN3). PKC is involved in receptor desensitization, in modulating membrane structure events, in regulating transcription, in mediating immune responses, in regulating cell growth, and in learning and memory. These functions are achieved by PKC-mediated phosphorylation of other proteins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16982
    Cercosporamide
    Inhibitor 99.0%
    Cercosporamide is a highly potent, ATP-competitive PKC kinase inhibitor targeting to PKC1, with an IC50 of <50 nM and a Ki of <7 nM. Cercosporamide is a unique Mnk inhibitor.
    Cercosporamide
  • HY-P5884A
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA
    Inhibitor 98.03%
    PKCθ pseudosubstrate peptide inhibitor, myristoylated TFA is a synthetic peptide that can be used to study the mechanism of action of PKCθ.
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA
  • HY-N2359
    Chelerythrine
    Antagonist
    Chelerythrine is a natural alkaloid, acts as a potent and selective Ca2+/phospholopid-dependent PKC antagonist, with an IC50 of 0.7 μM. Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity. Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μM and displaces Bax from BclXL. Chelerythrine triggers apoptosis and autophagy.
    Chelerythrine
  • HY-15141R
    Staurosporine (Standard)
    Inhibitor
    Staurosporine (Standard) is the analytical standard of Staurosporine. This product is intended for research and analytical applications. Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].
    Staurosporine (Standard)
  • HY-106029
    4α-TPA
    Control 99.0%
    4α-TPA is an inactive form of TPA, and is used as a negative control for TPA-activated events.
    4α-TPA
  • HY-P1401
    Protein Kinase C (19-36)
    Inhibitor 99.14%
    Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response.
    Protein Kinase C (19-36)
  • HY-P1286
    PKC β pseudosubstrate
    Inhibitor 99.37%
    PKC β pseudosubstrate is a selective cell-permeable inhibitor of PKC.
    PKC β pseudosubstrate
  • HY-148561
    CDK8-IN-12
    Inhibitor 99.74%
    CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with Kis of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent.
    CDK8-IN-12
  • HY-108600
    CGP-53353
    Inhibitor 98.87%
    CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients.
    CGP-53353
  • HY-129491
    O-Desmethyl Midostaurin
    Inhibitor
    O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism. O-Desmethyl Midostaurin can be used as an indicator for Midostaurin metabolism in vivo. Midostaurin is a multi-targeted protein kinase inhibitor with IC50 ranging from 22-500 nM.
    O-Desmethyl Midostaurin
  • HY-N8306
    Isojacareubin
    Inhibitor 98.0%
    Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis.
    Isojacareubin
  • HY-125957
    A-3 hydrochloride
    Inhibitor 99.75%
    A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively.
    A-3 hydrochloride
  • HY-106262
    Delcasertib
    Inhibitor 98.21%
    Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).
    Delcasertib
  • HY-RS11132
    Prkch Mouse Pre-designed siRNA Set A
    Inhibitor

    Prkch Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prkch gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Prkch Mouse Pre-designed siRNA Set A
  • HY-119817
    Flosequinan
    Inhibitor 99.95%
    Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure.
    Flosequinan
  • HY-108601A
    (S)-Ro 32-0432
    Inhibitor
    (S)-Ro 32-0432 is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC50 values of (S)-Ro 32-0432 for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research.
    (S)-Ro 32-0432
  • HY-108599A
    DCPLA-ME
    Activator 98.0%
    DCPLA-ME, the methyl ester form of DCPLA, is a potent PKCε activator for use in the treatment of neurodegenerative diseases.
    DCPLA-ME
  • HY-N6736
    K-252c
    Inhibitor ≥99.0%
    K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC50 of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase.
    K-252c
  • HY-RS11131
    PRKCH Human Pre-designed siRNA Set A
    Inhibitor

    PRKCH Human Pre-designed siRNA Set A contains three designed siRNAs for PRKCH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PRKCH Human Pre-designed siRNA Set A
  • HY-108262
    UCN-02
    Inhibitor ≥98.0%
    UCN-02 (7-epi-Hydroxystaurosporine) is a selective protein kinase C (PKC) inhibitor produced by Streptomyces strain N-12, with IC50s of 62 nM and 250 nM for PKC and protein kinase A (PKA), respectively. UCN-02 (7-epi-Hydroxystaurosporine) displays cytotoxic effect on the growth of HeLa S3 cells.
    UCN-02
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.